|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM152601244 |
| 003 |
DE-627 |
| 005 |
20231223062344.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0509.xml
|
| 035 |
|
|
|a (DE-627)NLM152601244
|
| 035 |
|
|
|a (NLM)15596410
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Pachot, Alexandre
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.02.2005
|
| 500 |
|
|
|a Date Revised 14.12.2004
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Success in treating severe sepsis will require relevant tools to monitor the patient immunoinflammatory status. This study aimed to investigate the feasibility of measuring a panel of immunological mediator mRNAs in whole blood and to study their prognostic values in septic shock patients. At the onset of shock, compared to healthy volunteers, mRNA levels in septic shock patients were increased for IL-10, IL-1beta, and high mobility group B1 (HMGB1) and decreased for transforming growth factor beta 1, the Th1, and Th2 transcription factors, T-bet and GATA-3, respectively. Single parameter analysis highlighted an increased expression of IL-10 and HMGB1 mRNA in nonsurvivors and a significant rise over time of GATA3 in survivors. Combining the expression levels of four genes, hierarchical cluster analysis showed that up to 95% of the patients with a similar outcome displayed transcriptional similarities. These results illustrate both the potential of whole blood mRNA quantification assays and the interest of a multiparametric strategy to better stratify septic patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a Transcription Factors
|2 NLM
|
| 700 |
1 |
|
|a Monneret, Guillaume
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Voirin, Nicolas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leissner, Philippe
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Venet, Fabienne
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bohé, Julien
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Payen, Didier
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bienvenu, Jacques
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mougin, Bruno
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lepape, Alain
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 114(2005), 1 vom: 10. Jan., Seite 61-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:114
|g year:2005
|g number:1
|g day:10
|g month:01
|g pages:61-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 114
|j 2005
|e 1
|b 10
|c 01
|h 61-9
|